PPIAP21: A Potential Drug Target and Biomarker (G170536)

Target Name: PPIAP21

NCBI ID: G170536

PPIAP21

Other Name(s): peptidylprolyl isomerase A pseudogene 21 | Peptidylprolyl isomerase A (cyclophilin A) pseudogene 21 | dJ269M15.1 | PPIAL

PPIAP21: A Potential Drug Target and Biomarker

PPIAP21 is a protein that is expressed in various tissues of the body, including the brain. Its function is not well understood, but it is known to be involved in the regulation of cellular processes that are critical for brain development and function. Several studies have suggested that PPIAP21 may have potential as a drug target or biomarker. In this article, we will explore the potential of PPIAP21 as a drug target and biomarker.

Drug Target Potential

PPIAP21 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. PPIAP21 is a protein that contains a unique farnesylated cysteine residue, which is known to be a critical structural component for protein stability and stability. This cysteine residue is also involved in the regulation of cellular processes that are critical for brain development and function.

Several studies have suggested that PPIAP21 may be a good drug target due to its involvement in the regulation of cellular processes that are critical for brain development and function. For example, several studies have shown that PPIAP21 is involved in the regulation of microRNA (miRNA) levels, which are small non-coding RNAs that play a critical role in regulating gene expression.

In addition, PPIAP21 has been shown to be involved in the regulation of protein translation, which is the process by which cells create new proteins from the instructions contained in their DNA. This suggests that PPIAP21 may be a good drug target for diseases that are characterized by the overproduction or underproduction of certain proteins.

Biomarker Potential

PPIAP21 has also been identified as a potential biomarker for several diseases. The expression of PPIAP21 has been shown to be increased in several diseases, including cancer, neurodegenerative diseases, and mood disorders. This suggests that PPIAP21 may be a useful biomarker for these diseases.

In addition, several studies have shown that the expression of PPIAP21 is decreased in several diseases, including cancer, neurodegenerative diseases, and mood disorders. This suggests that PPIAP21 may be a potential biomarker for these diseases.

Conclusion

In conclusion, PPIAP21 is a protein that has been identified as having potential as a drug target and biomarker. The unique structure and the involvement in various cellular processes make PPIAP21 an attractive target for drug development. Further studies are needed to fully understand its function and its potential as a drug and biomarker.

Protein Name: Peptidylprolyl Isomerase A Pseudogene 21

The "PPIAP21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAP21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets